Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

A phase II, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration 
31/12/2011

Foto54_1

The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

RESULTS: Patients receiving the combination of Fovista (1.5 mg) and Lucentis® gained a mean of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, compared to 6.5 letters for patients receiving Lucentis® monotherapy (p=0.019), representing a 62% additional benefit. No significant safety issues were observed for either treatment group in the trial.

Injections intravitréennesDMLA « sèche » ou atrophiqueDMLA exsudative ou humideRétinographieAutofluorescenceAngiographie en fluorescenceTomographie par cohérence optique
Last modified: 9 October, 2019 - 15:32